nodes	percent_of_prediction	percent_of_DWPC	metapath
Acetylcysteine—ACY1—kidney cancer	0.748	1	CbGaD
Acetylcysteine—Pyruvic acid—PDHB—kidney cancer	0.00518	1	CrCbGaD
Acetylcysteine—SLCO1B1—Pazopanib—kidney cancer	0.00392	1	CbGbCtD
Acetylcysteine—ACY1—renal system—kidney cancer	0.0025	0.113	CbGeAlD
Acetylcysteine—ACY1—kidney—kidney cancer	0.00242	0.109	CbGeAlD
Acetylcysteine—CHUK—renal system—kidney cancer	0.00173	0.0778	CbGeAlD
Acetylcysteine—SLC7A11—renal system—kidney cancer	0.00142	0.0641	CbGeAlD
Acetylcysteine—SLC7A11—kidney—kidney cancer	0.00137	0.0619	CbGeAlD
Acetylcysteine—GSS—nephron tubule—kidney cancer	0.00127	0.0571	CbGeAlD
Acetylcysteine—SLC22A6—nephron tubule—kidney cancer	0.00121	0.0545	CbGeAlD
Acetylcysteine—GSS—renal system—kidney cancer	0.00115	0.0519	CbGeAlD
Acetylcysteine—GSS—kidney—kidney cancer	0.00111	0.0502	CbGeAlD
Acetylcysteine—IKBKB—cortex of kidney—kidney cancer	0.0011	0.0498	CbGeAlD
Acetylcysteine—GSS—cortex of kidney—kidney cancer	0.00108	0.0489	CbGeAlD
Acetylcysteine—IKBKB—gonad—kidney cancer	0.00105	0.0474	CbGeAlD
Acetylcysteine—SLC22A6—cortex of kidney—kidney cancer	0.00103	0.0466	CbGeAlD
Acetylcysteine—GSS—gonad—kidney cancer	0.00103	0.0465	CbGeAlD
Acetylcysteine—GSS—cardiac atrium—kidney cancer	0.00103	0.0465	CbGeAlD
Acetylcysteine—SLCO1B1—renal system—kidney cancer	0.000846	0.0382	CbGeAlD
Acetylcysteine—SLCO1B1—kidney—kidney cancer	0.000818	0.0369	CbGeAlD
Acetylcysteine—Feeling hot—Doxorubicin—kidney cancer	0.000293	0.00285	CcSEcCtD
Acetylcysteine—Mediastinal disorder—Sunitinib—kidney cancer	0.000293	0.00285	CcSEcCtD
Acetylcysteine—Loss of consciousness—Erlotinib—kidney cancer	0.000287	0.0028	CcSEcCtD
Acetylcysteine—Eye pain—Capecitabine—kidney cancer	0.000287	0.00279	CcSEcCtD
Acetylcysteine—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000286	0.00279	CcSEcCtD
Acetylcysteine—Flushing—Dactinomycin—kidney cancer	0.000285	0.00278	CcSEcCtD
Acetylcysteine—Cough—Erlotinib—kidney cancer	0.000285	0.00278	CcSEcCtD
Acetylcysteine—Stomatitis—Gemcitabine—kidney cancer	0.000283	0.00276	CcSEcCtD
Acetylcysteine—Erythema—Sunitinib—kidney cancer	0.000283	0.00275	CcSEcCtD
Acetylcysteine—Nasopharyngitis—Paclitaxel—kidney cancer	0.000282	0.00275	CcSEcCtD
Acetylcysteine—Sweating—Gemcitabine—kidney cancer	0.000278	0.00271	CcSEcCtD
Acetylcysteine—Oedema—Everolimus—kidney cancer	0.000276	0.00269	CcSEcCtD
Acetylcysteine—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000276	0.00269	CcSEcCtD
Acetylcysteine—Hypersensitivity—Temsirolimus—kidney cancer	0.000274	0.00267	CcSEcCtD
Acetylcysteine—Shock—Everolimus—kidney cancer	0.000272	0.00265	CcSEcCtD
Acetylcysteine—Tachycardia—Everolimus—kidney cancer	0.00027	0.00263	CcSEcCtD
Acetylcysteine—Angioedema—Sorafenib—kidney cancer	0.000268	0.00262	CcSEcCtD
Acetylcysteine—Skin disorder—Everolimus—kidney cancer	0.000268	0.00261	CcSEcCtD
Acetylcysteine—Erythema—Dactinomycin—kidney cancer	0.000268	0.00261	CcSEcCtD
Acetylcysteine—Hyperhidrosis—Everolimus—kidney cancer	0.000267	0.0026	CcSEcCtD
Acetylcysteine—Oedema—Erlotinib—kidney cancer	0.000266	0.0026	CcSEcCtD
Acetylcysteine—Syncope—Sorafenib—kidney cancer	0.000263	0.00257	CcSEcCtD
Acetylcysteine—Pruritus—Temsirolimus—kidney cancer	0.000263	0.00256	CcSEcCtD
Acetylcysteine—Shock—Erlotinib—kidney cancer	0.000262	0.00255	CcSEcCtD
Acetylcysteine—Skin disorder—Erlotinib—kidney cancer	0.000259	0.00252	CcSEcCtD
Acetylcysteine—Pharyngitis—Gemcitabine—kidney cancer	0.000259	0.00252	CcSEcCtD
Acetylcysteine—Angioedema—Sunitinib—kidney cancer	0.000258	0.00252	CcSEcCtD
Acetylcysteine—Loss of consciousness—Sorafenib—kidney cancer	0.000258	0.00252	CcSEcCtD
Acetylcysteine—Hypotension—Everolimus—kidney cancer	0.000258	0.00251	CcSEcCtD
Acetylcysteine—Cough—Sorafenib—kidney cancer	0.000256	0.0025	CcSEcCtD
Acetylcysteine—Cardiac disorder—Vincristine—kidney cancer	0.000255	0.00248	CcSEcCtD
Acetylcysteine—Thinking abnormal—Doxorubicin—kidney cancer	0.000251	0.00245	CcSEcCtD
Acetylcysteine—Face oedema—Capecitabine—kidney cancer	0.00025	0.00243	CcSEcCtD
Acetylcysteine—Angiopathy—Vincristine—kidney cancer	0.000249	0.00243	CcSEcCtD
Acetylcysteine—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000248	0.00242	CcSEcCtD
Acetylcysteine—Mediastinal disorder—Vincristine—kidney cancer	0.000248	0.00241	CcSEcCtD
Acetylcysteine—Pruritus—Pazopanib—kidney cancer	0.000247	0.00241	CcSEcCtD
Acetylcysteine—Cough—Sunitinib—kidney cancer	0.000247	0.0024	CcSEcCtD
Acetylcysteine—Dyspnoea—Everolimus—kidney cancer	0.000246	0.0024	CcSEcCtD
Acetylcysteine—Somnolence—Everolimus—kidney cancer	0.000246	0.00239	CcSEcCtD
Acetylcysteine—Dizziness—Temsirolimus—kidney cancer	0.000246	0.00239	CcSEcCtD
Acetylcysteine—Dyspepsia—Everolimus—kidney cancer	0.000243	0.00237	CcSEcCtD
Acetylcysteine—Cardiac disorder—Gemcitabine—kidney cancer	0.000242	0.00236	CcSEcCtD
Acetylcysteine—Anaphylactic shock—Sorafenib—kidney cancer	0.00024	0.00234	CcSEcCtD
Acetylcysteine—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000239	0.00233	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Everolimus—kidney cancer	0.000238	0.00232	CcSEcCtD
Acetylcysteine—Dyspnoea—Erlotinib—kidney cancer	0.000238	0.00232	CcSEcCtD
Acetylcysteine—Stomatitis—Paclitaxel—kidney cancer	0.000237	0.00231	CcSEcCtD
Acetylcysteine—Angiopathy—Gemcitabine—kidney cancer	0.000236	0.0023	CcSEcCtD
Acetylcysteine—Vomiting—Temsirolimus—kidney cancer	0.000236	0.0023	CcSEcCtD
Acetylcysteine—Shock—Sorafenib—kidney cancer	0.000236	0.0023	CcSEcCtD
Acetylcysteine—Gait disturbance—Doxorubicin—kidney cancer	0.000235	0.00229	CcSEcCtD
Acetylcysteine—Immune system disorder—Gemcitabine—kidney cancer	0.000235	0.00229	CcSEcCtD
Acetylcysteine—Mediastinal disorder—Gemcitabine—kidney cancer	0.000235	0.00229	CcSEcCtD
Acetylcysteine—Dyspepsia—Erlotinib—kidney cancer	0.000235	0.00229	CcSEcCtD
Acetylcysteine—Rash—Temsirolimus—kidney cancer	0.000234	0.00228	CcSEcCtD
Acetylcysteine—Dermatitis—Temsirolimus—kidney cancer	0.000234	0.00228	CcSEcCtD
Acetylcysteine—Skin disorder—Sorafenib—kidney cancer	0.000233	0.00227	CcSEcCtD
Acetylcysteine—Nasopharyngitis—Capecitabine—kidney cancer	0.000231	0.00225	CcSEcCtD
Acetylcysteine—Dizziness—Pazopanib—kidney cancer	0.000231	0.00225	CcSEcCtD
Acetylcysteine—Oedema—Sunitinib—kidney cancer	0.000231	0.00225	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Erlotinib—kidney cancer	0.00023	0.00224	CcSEcCtD
Acetylcysteine—Shock—Sunitinib—kidney cancer	0.000227	0.00221	CcSEcCtD
Acetylcysteine—Erythema—Gemcitabine—kidney cancer	0.000227	0.00221	CcSEcCtD
Acetylcysteine—Skin disorder—Sunitinib—kidney cancer	0.000224	0.00218	CcSEcCtD
Acetylcysteine—Asthma—Capecitabine—kidney cancer	0.000224	0.00218	CcSEcCtD
Acetylcysteine—Vomiting—Pazopanib—kidney cancer	0.000222	0.00217	CcSEcCtD
Acetylcysteine—Rash—Pazopanib—kidney cancer	0.000221	0.00215	CcSEcCtD
Acetylcysteine—Nausea—Temsirolimus—kidney cancer	0.000221	0.00215	CcSEcCtD
Acetylcysteine—Dermatitis—Pazopanib—kidney cancer	0.00022	0.00215	CcSEcCtD
Acetylcysteine—Bronchospasm—Capecitabine—kidney cancer	0.00022	0.00214	CcSEcCtD
Acetylcysteine—Oedema—Dactinomycin—kidney cancer	0.000218	0.00213	CcSEcCtD
Acetylcysteine—Body temperature increased—Everolimus—kidney cancer	0.000218	0.00213	CcSEcCtD
Acetylcysteine—Pharyngitis—Paclitaxel—kidney cancer	0.000216	0.00211	CcSEcCtD
Acetylcysteine—Dyspnoea—Sorafenib—kidney cancer	0.000214	0.00208	CcSEcCtD
Acetylcysteine—Dyspepsia—Sorafenib—kidney cancer	0.000211	0.00206	CcSEcCtD
Acetylcysteine—Body temperature increased—Erlotinib—kidney cancer	0.000211	0.00205	CcSEcCtD
Acetylcysteine—Nausea—Pazopanib—kidney cancer	0.000208	0.00202	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000207	0.00202	CcSEcCtD
Acetylcysteine—Dyspnoea—Sunitinib—kidney cancer	0.000206	0.002	CcSEcCtD
Acetylcysteine—Hypersensitivity—Vinblastine—kidney cancer	0.000204	0.00199	CcSEcCtD
Acetylcysteine—Hypersensitivity—Everolimus—kidney cancer	0.000203	0.00198	CcSEcCtD
Acetylcysteine—Dyspepsia—Sunitinib—kidney cancer	0.000203	0.00198	CcSEcCtD
Acetylcysteine—Flushing—Paclitaxel—kidney cancer	0.000202	0.00197	CcSEcCtD
Acetylcysteine—Cardiac disorder—Paclitaxel—kidney cancer	0.000202	0.00197	CcSEcCtD
Acetylcysteine—Mental disability—Doxorubicin—kidney cancer	0.000199	0.00194	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000199	0.00194	CcSEcCtD
Acetylcysteine—Cough—Gemcitabine—kidney cancer	0.000198	0.00193	CcSEcCtD
Acetylcysteine—Angiopathy—Paclitaxel—kidney cancer	0.000198	0.00193	CcSEcCtD
Acetylcysteine—Immune system disorder—Paclitaxel—kidney cancer	0.000197	0.00192	CcSEcCtD
Acetylcysteine—Mediastinal disorder—Paclitaxel—kidney cancer	0.000197	0.00192	CcSEcCtD
Acetylcysteine—Pruritus—Everolimus—kidney cancer	0.000195	0.0019	CcSEcCtD
Acetylcysteine—Oedema—Vincristine—kidney cancer	0.000195	0.0019	CcSEcCtD
Acetylcysteine—Anaphylactic shock—Vincristine—kidney cancer	0.000195	0.0019	CcSEcCtD
Acetylcysteine—Stomatitis—Capecitabine—kidney cancer	0.000194	0.00189	CcSEcCtD
Acetylcysteine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000192	0.00187	CcSEcCtD
Acetylcysteine—Urticaria—Sorafenib—kidney cancer	0.00019	0.00186	CcSEcCtD
Acetylcysteine—Erythema—Paclitaxel—kidney cancer	0.00019	0.00185	CcSEcCtD
Acetylcysteine—Body temperature increased—Sorafenib—kidney cancer	0.00019	0.00185	CcSEcCtD
Acetylcysteine—Hyperhidrosis—Vincristine—kidney cancer	0.000189	0.00184	CcSEcCtD
Acetylcysteine—Pruritus—Erlotinib—kidney cancer	0.000189	0.00184	CcSEcCtD
Acetylcysteine—Oedema—Gemcitabine—kidney cancer	0.000185	0.0018	CcSEcCtD
Acetylcysteine—Anaphylactic shock—Gemcitabine—kidney cancer	0.000185	0.0018	CcSEcCtD
Acetylcysteine—Eye pain—Doxorubicin—kidney cancer	0.000185	0.0018	CcSEcCtD
Acetylcysteine—Dizziness—Vinblastine—kidney cancer	0.000183	0.00179	CcSEcCtD
Acetylcysteine—Dizziness—Everolimus—kidney cancer	0.000183	0.00178	CcSEcCtD
Acetylcysteine—Body temperature increased—Sunitinib—kidney cancer	0.000182	0.00178	CcSEcCtD
Acetylcysteine—Hypotension—Vincristine—kidney cancer	0.000182	0.00178	CcSEcCtD
Acetylcysteine—Skin disorder—Gemcitabine—kidney cancer	0.00018	0.00175	CcSEcCtD
Acetylcysteine—Hyperhidrosis—Gemcitabine—kidney cancer	0.000179	0.00174	CcSEcCtD
Acetylcysteine—Pharyngitis—Capecitabine—kidney cancer	0.000178	0.00173	CcSEcCtD
Acetylcysteine—Hypersensitivity—Sorafenib—kidney cancer	0.000177	0.00172	CcSEcCtD
Acetylcysteine—Vomiting—Vinblastine—kidney cancer	0.000176	0.00172	CcSEcCtD
Acetylcysteine—Dizziness—Erlotinib—kidney cancer	0.000176	0.00172	CcSEcCtD
Acetylcysteine—Vomiting—Everolimus—kidney cancer	0.000176	0.00171	CcSEcCtD
Acetylcysteine—Rash—Everolimus—kidney cancer	0.000174	0.0017	CcSEcCtD
Acetylcysteine—Dermatitis—Everolimus—kidney cancer	0.000174	0.0017	CcSEcCtD
Acetylcysteine—Angioedema—Paclitaxel—kidney cancer	0.000174	0.00169	CcSEcCtD
Acetylcysteine—Hypotension—Gemcitabine—kidney cancer	0.000173	0.00169	CcSEcCtD
Acetylcysteine—Body temperature increased—Dactinomycin—kidney cancer	0.000173	0.00168	CcSEcCtD
Acetylcysteine—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.000172	0.00168	CcSEcCtD
Acetylcysteine—Syncope—Paclitaxel—kidney cancer	0.00017	0.00166	CcSEcCtD
Acetylcysteine—Hypersensitivity—Sunitinib—kidney cancer	0.00017	0.00166	CcSEcCtD
Acetylcysteine—Pruritus—Sorafenib—kidney cancer	0.00017	0.00165	CcSEcCtD
Acetylcysteine—Vomiting—Erlotinib—kidney cancer	0.000169	0.00165	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Vincristine—kidney cancer	0.000168	0.00164	CcSEcCtD
Acetylcysteine—Rash—Erlotinib—kidney cancer	0.000168	0.00164	CcSEcCtD
Acetylcysteine—Dermatitis—Erlotinib—kidney cancer	0.000168	0.00164	CcSEcCtD
Acetylcysteine—Loss of consciousness—Paclitaxel—kidney cancer	0.000167	0.00163	CcSEcCtD
Acetylcysteine—Flushing—Capecitabine—kidney cancer	0.000166	0.00162	CcSEcCtD
Acetylcysteine—Cardiac disorder—Capecitabine—kidney cancer	0.000166	0.00162	CcSEcCtD
Acetylcysteine—Cough—Paclitaxel—kidney cancer	0.000166	0.00161	CcSEcCtD
Acetylcysteine—Dyspnoea—Gemcitabine—kidney cancer	0.000165	0.00161	CcSEcCtD
Acetylcysteine—Nausea—Vinblastine—kidney cancer	0.000165	0.0016	CcSEcCtD
Acetylcysteine—Somnolence—Gemcitabine—kidney cancer	0.000165	0.0016	CcSEcCtD
Acetylcysteine—Nausea—Everolimus—kidney cancer	0.000164	0.0016	CcSEcCtD
Acetylcysteine—Pruritus—Sunitinib—kidney cancer	0.000163	0.00159	CcSEcCtD
Acetylcysteine—Angiopathy—Capecitabine—kidney cancer	0.000162	0.00158	CcSEcCtD
Acetylcysteine—Immune system disorder—Capecitabine—kidney cancer	0.000162	0.00158	CcSEcCtD
Acetylcysteine—Mediastinal disorder—Capecitabine—kidney cancer	0.000161	0.00157	CcSEcCtD
Acetylcysteine—Face oedema—Doxorubicin—kidney cancer	0.000161	0.00157	CcSEcCtD
Acetylcysteine—Hypersensitivity—Dactinomycin—kidney cancer	0.000161	0.00157	CcSEcCtD
Acetylcysteine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000161	0.00156	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00016	0.00156	CcSEcCtD
Acetylcysteine—Dizziness—Sorafenib—kidney cancer	0.000159	0.00154	CcSEcCtD
Acetylcysteine—Nausea—Erlotinib—kidney cancer	0.000158	0.00154	CcSEcCtD
Acetylcysteine—Erythema—Capecitabine—kidney cancer	0.000156	0.00152	CcSEcCtD
Acetylcysteine—Anaphylactic shock—Paclitaxel—kidney cancer	0.000155	0.00151	CcSEcCtD
Acetylcysteine—Oedema—Paclitaxel—kidney cancer	0.000155	0.00151	CcSEcCtD
Acetylcysteine—Body temperature increased—Vincristine—kidney cancer	0.000154	0.0015	CcSEcCtD
Acetylcysteine—Dizziness—Sunitinib—kidney cancer	0.000153	0.00149	CcSEcCtD
Acetylcysteine—Shock—Paclitaxel—kidney cancer	0.000152	0.00149	CcSEcCtD
Acetylcysteine—Vomiting—Sorafenib—kidney cancer	0.000152	0.00149	CcSEcCtD
Acetylcysteine—Tachycardia—Paclitaxel—kidney cancer	0.000151	0.00147	CcSEcCtD
Acetylcysteine—Rash—Sorafenib—kidney cancer	0.000151	0.00147	CcSEcCtD
Acetylcysteine—Dermatitis—Sorafenib—kidney cancer	0.000151	0.00147	CcSEcCtD
Acetylcysteine—Skin disorder—Paclitaxel—kidney cancer	0.000151	0.00147	CcSEcCtD
Acetylcysteine—Hyperhidrosis—Paclitaxel—kidney cancer	0.00015	0.00146	CcSEcCtD
Acetylcysteine—Nasopharyngitis—Doxorubicin—kidney cancer	0.000149	0.00145	CcSEcCtD
Acetylcysteine—Vomiting—Sunitinib—kidney cancer	0.000147	0.00143	CcSEcCtD
Acetylcysteine—Body temperature increased—Gemcitabine—kidney cancer	0.000146	0.00143	CcSEcCtD
Acetylcysteine—Rash—Sunitinib—kidney cancer	0.000145	0.00142	CcSEcCtD
Acetylcysteine—Dermatitis—Sunitinib—kidney cancer	0.000145	0.00142	CcSEcCtD
Acetylcysteine—Hypotension—Paclitaxel—kidney cancer	0.000145	0.00141	CcSEcCtD
Acetylcysteine—Asthma—Doxorubicin—kidney cancer	0.000144	0.0014	CcSEcCtD
Acetylcysteine—Hypersensitivity—Vincristine—kidney cancer	0.000144	0.0014	CcSEcCtD
Acetylcysteine—Nausea—Sorafenib—kidney cancer	0.000142	0.00139	CcSEcCtD
Acetylcysteine—Syncope—Capecitabine—kidney cancer	0.00014	0.00136	CcSEcCtD
Acetylcysteine—Vomiting—Dactinomycin—kidney cancer	0.000139	0.00135	CcSEcCtD
Acetylcysteine—Dyspnoea—Paclitaxel—kidney cancer	0.000138	0.00135	CcSEcCtD
Acetylcysteine—Somnolence—Paclitaxel—kidney cancer	0.000138	0.00134	CcSEcCtD
Acetylcysteine—Rash—Dactinomycin—kidney cancer	0.000138	0.00134	CcSEcCtD
Acetylcysteine—Nausea—Sunitinib—kidney cancer	0.000137	0.00134	CcSEcCtD
Acetylcysteine—Loss of consciousness—Capecitabine—kidney cancer	0.000137	0.00133	CcSEcCtD
Acetylcysteine—Dyspepsia—Paclitaxel—kidney cancer	0.000136	0.00133	CcSEcCtD
Acetylcysteine—Cough—Capecitabine—kidney cancer	0.000136	0.00133	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000134	0.0013	CcSEcCtD
Acetylcysteine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000132	0.00128	CcSEcCtD
Acetylcysteine—Pruritus—Gemcitabine—kidney cancer	0.000131	0.00128	CcSEcCtD
Acetylcysteine—Nausea—Dactinomycin—kidney cancer	0.00013	0.00126	CcSEcCtD
Acetylcysteine—Dizziness—Vincristine—kidney cancer	0.000129	0.00126	CcSEcCtD
Acetylcysteine—Drowsiness—Doxorubicin—kidney cancer	0.000129	0.00125	CcSEcCtD
Acetylcysteine—Oedema—Capecitabine—kidney cancer	0.000127	0.00124	CcSEcCtD
Acetylcysteine—Stomatitis—Doxorubicin—kidney cancer	0.000125	0.00122	CcSEcCtD
Acetylcysteine—Shock—Capecitabine—kidney cancer	0.000125	0.00122	CcSEcCtD
Acetylcysteine—Tachycardia—Capecitabine—kidney cancer	0.000124	0.00121	CcSEcCtD
Acetylcysteine—Vomiting—Vincristine—kidney cancer	0.000124	0.00121	CcSEcCtD
Acetylcysteine—Skin disorder—Capecitabine—kidney cancer	0.000124	0.0012	CcSEcCtD
Acetylcysteine—Sweating—Doxorubicin—kidney cancer	0.000123	0.0012	CcSEcCtD
Acetylcysteine—Urticaria—Paclitaxel—kidney cancer	0.000123	0.0012	CcSEcCtD
Acetylcysteine—Rash—Vincristine—kidney cancer	0.000123	0.0012	CcSEcCtD
Acetylcysteine—Hyperhidrosis—Capecitabine—kidney cancer	0.000123	0.0012	CcSEcCtD
Acetylcysteine—Dermatitis—Vincristine—kidney cancer	0.000123	0.0012	CcSEcCtD
Acetylcysteine—Body temperature increased—Paclitaxel—kidney cancer	0.000123	0.00119	CcSEcCtD
Acetylcysteine—Hypotension—Capecitabine—kidney cancer	0.000119	0.00116	CcSEcCtD
Acetylcysteine—Vomiting—Gemcitabine—kidney cancer	0.000118	0.00115	CcSEcCtD
Acetylcysteine—Rash—Gemcitabine—kidney cancer	0.000117	0.00114	CcSEcCtD
Acetylcysteine—Dermatitis—Gemcitabine—kidney cancer	0.000117	0.00114	CcSEcCtD
Acetylcysteine—Nausea—Vincristine—kidney cancer	0.000116	0.00113	CcSEcCtD
Acetylcysteine—Pharyngitis—Doxorubicin—kidney cancer	0.000115	0.00112	CcSEcCtD
Acetylcysteine—Hypersensitivity—Paclitaxel—kidney cancer	0.000114	0.00111	CcSEcCtD
Acetylcysteine—Dyspnoea—Capecitabine—kidney cancer	0.000113	0.0011	CcSEcCtD
Acetylcysteine—Dyspepsia—Capecitabine—kidney cancer	0.000112	0.00109	CcSEcCtD
Acetylcysteine—Nausea—Gemcitabine—kidney cancer	0.00011	0.00107	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00011	0.00107	CcSEcCtD
Acetylcysteine—Pruritus—Paclitaxel—kidney cancer	0.00011	0.00107	CcSEcCtD
Acetylcysteine—Flushing—Doxorubicin—kidney cancer	0.000107	0.00104	CcSEcCtD
Acetylcysteine—Cardiac disorder—Doxorubicin—kidney cancer	0.000107	0.00104	CcSEcCtD
Acetylcysteine—Angiopathy—Doxorubicin—kidney cancer	0.000105	0.00102	CcSEcCtD
Acetylcysteine—Immune system disorder—Doxorubicin—kidney cancer	0.000104	0.00102	CcSEcCtD
Acetylcysteine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000104	0.00101	CcSEcCtD
Acetylcysteine—Dizziness—Paclitaxel—kidney cancer	0.000102	0.000999	CcSEcCtD
Acetylcysteine—Urticaria—Capecitabine—kidney cancer	0.000101	0.000985	CcSEcCtD
Acetylcysteine—Body temperature increased—Capecitabine—kidney cancer	0.000101	0.00098	CcSEcCtD
Acetylcysteine—Erythema—Doxorubicin—kidney cancer	0.0001	0.000979	CcSEcCtD
Acetylcysteine—Vomiting—Paclitaxel—kidney cancer	9.85e-05	0.00096	CcSEcCtD
Acetylcysteine—Rash—Paclitaxel—kidney cancer	9.77e-05	0.000952	CcSEcCtD
Acetylcysteine—Dermatitis—Paclitaxel—kidney cancer	9.76e-05	0.000951	CcSEcCtD
Acetylcysteine—Hypersensitivity—Capecitabine—kidney cancer	9.37e-05	0.000913	CcSEcCtD
Acetylcysteine—Nausea—Paclitaxel—kidney cancer	9.21e-05	0.000897	CcSEcCtD
Acetylcysteine—Syncope—Doxorubicin—kidney cancer	9.01e-05	0.000878	CcSEcCtD
Acetylcysteine—Pruritus—Capecitabine—kidney cancer	9e-05	0.000877	CcSEcCtD
Acetylcysteine—Loss of consciousness—Doxorubicin—kidney cancer	8.83e-05	0.00086	CcSEcCtD
Acetylcysteine—Cough—Doxorubicin—kidney cancer	8.77e-05	0.000854	CcSEcCtD
Acetylcysteine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	8.49e-05	0.000828	CcSEcCtD
Acetylcysteine—Dizziness—Capecitabine—kidney cancer	8.41e-05	0.00082	CcSEcCtD
Acetylcysteine—Oedema—Doxorubicin—kidney cancer	8.2e-05	0.000799	CcSEcCtD
Acetylcysteine—Anaphylactic shock—Doxorubicin—kidney cancer	8.2e-05	0.000799	CcSEcCtD
Acetylcysteine—Vomiting—Capecitabine—kidney cancer	8.09e-05	0.000788	CcSEcCtD
Acetylcysteine—Shock—Doxorubicin—kidney cancer	8.07e-05	0.000786	CcSEcCtD
Acetylcysteine—Rash—Capecitabine—kidney cancer	8.02e-05	0.000781	CcSEcCtD
Acetylcysteine—Dermatitis—Capecitabine—kidney cancer	8.01e-05	0.000781	CcSEcCtD
Acetylcysteine—Tachycardia—Doxorubicin—kidney cancer	8e-05	0.00078	CcSEcCtD
Acetylcysteine—Skin disorder—Doxorubicin—kidney cancer	7.96e-05	0.000776	CcSEcCtD
Acetylcysteine—Hyperhidrosis—Doxorubicin—kidney cancer	7.93e-05	0.000772	CcSEcCtD
Acetylcysteine—Hypotension—Doxorubicin—kidney cancer	7.66e-05	0.000746	CcSEcCtD
Acetylcysteine—Nausea—Capecitabine—kidney cancer	7.55e-05	0.000736	CcSEcCtD
Acetylcysteine—Dyspnoea—Doxorubicin—kidney cancer	7.31e-05	0.000712	CcSEcCtD
Acetylcysteine—Somnolence—Doxorubicin—kidney cancer	7.29e-05	0.00071	CcSEcCtD
Acetylcysteine—Dyspepsia—Doxorubicin—kidney cancer	7.22e-05	0.000703	CcSEcCtD
Acetylcysteine—Gastrointestinal disorder—Doxorubicin—kidney cancer	7.08e-05	0.00069	CcSEcCtD
Acetylcysteine—Urticaria—Doxorubicin—kidney cancer	6.51e-05	0.000635	CcSEcCtD
Acetylcysteine—Body temperature increased—Doxorubicin—kidney cancer	6.48e-05	0.000632	CcSEcCtD
Acetylcysteine—Hypersensitivity—Doxorubicin—kidney cancer	6.04e-05	0.000589	CcSEcCtD
Acetylcysteine—Pruritus—Doxorubicin—kidney cancer	5.8e-05	0.000565	CcSEcCtD
Acetylcysteine—Dizziness—Doxorubicin—kidney cancer	5.42e-05	0.000528	CcSEcCtD
Acetylcysteine—Vomiting—Doxorubicin—kidney cancer	5.21e-05	0.000508	CcSEcCtD
Acetylcysteine—Rash—Doxorubicin—kidney cancer	5.17e-05	0.000504	CcSEcCtD
Acetylcysteine—Dermatitis—Doxorubicin—kidney cancer	5.16e-05	0.000503	CcSEcCtD
Acetylcysteine—Nausea—Doxorubicin—kidney cancer	4.87e-05	0.000475	CcSEcCtD
Acetylcysteine—CHUK—Signaling Pathways—CASP2—kidney cancer	1.44e-05	0.000122	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—TSC2—kidney cancer	1.44e-05	0.000122	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—PSMD7—kidney cancer	1.44e-05	0.000122	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—PAK1—kidney cancer	1.43e-05	0.000121	CbGpPWpGaD
Acetylcysteine—ACY1—Metabolism—PIK3CA—kidney cancer	1.42e-05	0.00012	CbGpPWpGaD
Acetylcysteine—CHUK—Cytokine Signaling in Immune system—MAPK3—kidney cancer	1.42e-05	0.00012	CbGpPWpGaD
Acetylcysteine—IKBKB—B Cell Activation—PIK3CA—kidney cancer	1.42e-05	0.00012	CbGpPWpGaD
Acetylcysteine—GRIN1—Developmental Biology—VEGFA—kidney cancer	1.41e-05	0.000119	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—KIT—kidney cancer	1.41e-05	0.000119	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling by NGF—MAPK3—kidney cancer	1.4e-05	0.000118	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—IFNA1—kidney cancer	1.39e-05	0.000118	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—TSC2—kidney cancer	1.39e-05	0.000117	CbGpPWpGaD
Acetylcysteine—GRIN2B—Developmental Biology—VEGFA—kidney cancer	1.37e-05	0.000116	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—KIT—kidney cancer	1.35e-05	0.000114	CbGpPWpGaD
Acetylcysteine—CHUK—Cytokine Signaling in Immune system—MAPK1—kidney cancer	1.35e-05	0.000114	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—EGR1—kidney cancer	1.34e-05	0.000113	CbGpPWpGaD
Acetylcysteine—GRIN1—Developmental Biology—MAPK3—kidney cancer	1.33e-05	0.000112	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—SLC2A1—kidney cancer	1.33e-05	0.000112	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling by NGF—MAPK1—kidney cancer	1.33e-05	0.000112	CbGpPWpGaD
Acetylcysteine—GSS—Metabolism—PTGS2—kidney cancer	1.33e-05	0.000112	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—CRABP1—kidney cancer	1.33e-05	0.000112	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—GRB7—kidney cancer	1.32e-05	0.000111	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—JUNB—kidney cancer	1.32e-05	0.000111	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—AKAP13—kidney cancer	1.31e-05	0.00011	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—CASP2—kidney cancer	1.31e-05	0.00011	CbGpPWpGaD
Acetylcysteine—GRIN2B—Developmental Biology—MAPK3—kidney cancer	1.3e-05	0.00011	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—IFNA2—kidney cancer	1.3e-05	0.000109	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—PAK1—kidney cancer	1.3e-05	0.000109	CbGpPWpGaD
Acetylcysteine—IKBKB—Cytokine Signaling in Immune system—MAPK3—kidney cancer	1.29e-05	0.000109	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—KIT—kidney cancer	1.28e-05	0.000108	CbGpPWpGaD
Acetylcysteine—CHUK—Cytokine Signaling in Immune system—KRAS—kidney cancer	1.28e-05	0.000108	CbGpPWpGaD
Acetylcysteine—GRIN1—Developmental Biology—MAPK1—kidney cancer	1.27e-05	0.000107	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling by NGF—MAPK3—kidney cancer	1.27e-05	0.000107	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—IFNA1—kidney cancer	1.26e-05	0.000107	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling by NGF—KRAS—kidney cancer	1.25e-05	0.000106	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—CDH1—kidney cancer	1.24e-05	0.000105	CbGpPWpGaD
Acetylcysteine—GRIN2B—Developmental Biology—MAPK1—kidney cancer	1.24e-05	0.000104	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—ITPR2—kidney cancer	1.23e-05	0.000104	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—ITPR2—kidney cancer	1.23e-05	0.000104	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—KIT—kidney cancer	1.22e-05	0.000103	CbGpPWpGaD
Acetylcysteine—IKBKB—Cytokine Signaling in Immune system—MAPK1—kidney cancer	1.22e-05	0.000103	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—EGR1—kidney cancer	1.21e-05	0.000102	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling by NGF—MAPK1—kidney cancer	1.2e-05	0.000102	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—GRB7—kidney cancer	1.2e-05	0.000101	CbGpPWpGaD
Acetylcysteine—GRIN1—Developmental Biology—KRAS—kidney cancer	1.2e-05	0.000101	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—IFNA2—kidney cancer	1.18e-05	9.92e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Cytokine Signaling in Immune system—PIK3CA—kidney cancer	1.17e-05	9.88e-05	CbGpPWpGaD
Acetylcysteine—GRIN2B—Developmental Biology—KRAS—kidney cancer	1.17e-05	9.84e-05	CbGpPWpGaD
Acetylcysteine—GSS—Metabolism—PTEN—kidney cancer	1.16e-05	9.75e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Cytokine Signaling in Immune system—KRAS—kidney cancer	1.16e-05	9.75e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling by NGF—PIK3CA—kidney cancer	1.15e-05	9.72e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling by NGF—KRAS—kidney cancer	1.14e-05	9.59e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.14e-05	9.58e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—CDH1—kidney cancer	1.13e-05	9.51e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—GSTT1—kidney cancer	1.12e-05	9.48e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—ACHE—kidney cancer	1.12e-05	9.48e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—ITPR2—kidney cancer	1.11e-05	9.39e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—CTNNA1—kidney cancer	1.11e-05	9.39e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—HSPB1—kidney cancer	1.11e-05	9.34e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—EIF4EBP1—kidney cancer	1.11e-05	9.34e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—RAF1—kidney cancer	1.1e-05	9.31e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—RELA—kidney cancer	1.1e-05	9.27e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—ERBB2—kidney cancer	1.09e-05	9.21e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—CD8A—kidney cancer	1.09e-05	9.2e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—MTOR—kidney cancer	1.08e-05	9.09e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—CD4—kidney cancer	1.08e-05	9.07e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—CDKN2B—kidney cancer	1.07e-05	9.06e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—SCARB1—kidney cancer	1.06e-05	8.97e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Cytokine Signaling in Immune system—PIK3CA—kidney cancer	1.06e-05	8.96e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—RAF1—kidney cancer	1.06e-05	8.94e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—RELA—kidney cancer	1.06e-05	8.9e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—PTGS1—kidney cancer	1.05e-05	8.88e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—ERBB2—kidney cancer	1.05e-05	8.85e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling by NGF—PIK3CA—kidney cancer	1.04e-05	8.81e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—MTOR—kidney cancer	1.03e-05	8.73e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—CD4—kidney cancer	1.03e-05	8.71e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—PSMD7—kidney cancer	1.03e-05	8.71e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—TSC1—kidney cancer	1.03e-05	8.68e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—ANXA1—kidney cancer	1.03e-05	8.68e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—PSMD7—kidney cancer	1.03e-05	8.68e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—CDKN1B—kidney cancer	1.01e-05	8.53e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—CTNNA1—kidney cancer	1.01e-05	8.52e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—HSPB1—kidney cancer	1e-05	8.47e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—EIF4EBP1—kidney cancer	1e-05	8.47e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—RAF1—kidney cancer	1e-05	8.44e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—FLT1—kidney cancer	9.97e-06	8.41e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—RELA—kidney cancer	9.97e-06	8.41e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—ERBB2—kidney cancer	9.9e-06	8.35e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—CD8A—kidney cancer	9.89e-06	8.34e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—BCHE—kidney cancer	9.79e-06	8.25e-05	CbGpPWpGaD
Acetylcysteine—SLC22A6—Transmembrane transport of small molecules—RAF1—kidney cancer	9.79e-06	8.25e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—MTOR—kidney cancer	9.77e-06	8.24e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—CD4—kidney cancer	9.75e-06	8.23e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—CDKN1B—kidney cancer	9.71e-06	8.19e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—SLC5A5—kidney cancer	9.67e-06	8.15e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—JUN—kidney cancer	9.63e-06	8.12e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—RAF1—kidney cancer	9.61e-06	8.11e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—RELA—kidney cancer	9.57e-06	8.07e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—CTNNB1—kidney cancer	9.56e-06	8.06e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—ERBB2—kidney cancer	9.51e-06	8.02e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—MTOR—kidney cancer	9.38e-06	7.92e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—CD4—kidney cancer	9.37e-06	7.9e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—SLC2A1—kidney cancer	9.34e-06	7.87e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—ANXA1—kidney cancer	9.33e-06	7.87e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—PSMD7—kidney cancer	9.33e-06	7.87e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—TSC1—kidney cancer	9.33e-06	7.87e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—PTEN—kidney cancer	9.31e-06	7.86e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—TSC2—kidney cancer	9.28e-06	7.82e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—JUNB—kidney cancer	9.24e-06	7.79e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—PAK1—kidney cancer	9.24e-06	7.79e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—CDKN1B—kidney cancer	9.17e-06	7.74e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	9.06e-06	7.64e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—FLT1—kidney cancer	9.04e-06	7.62e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—PTEN—kidney cancer	8.94e-06	7.54e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Transmembrane transport of small molecules—RAF1—kidney cancer	8.9e-06	7.51e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—CDKN1B—kidney cancer	8.81e-06	7.43e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—JUN—kidney cancer	8.73e-06	7.36e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—CTNNB1—kidney cancer	8.66e-06	7.31e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—HIF1A—kidney cancer	8.59e-06	7.24e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—TSC2—kidney cancer	8.56e-06	7.22e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—PTEN—kidney cancer	8.44e-06	7.12e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—TSC2—kidney cancer	8.41e-06	7.09e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—PAK1—kidney cancer	8.38e-06	7.07e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—JUNB—kidney cancer	8.38e-06	7.07e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—KIT—kidney cancer	8.19e-06	6.91e-05	CbGpPWpGaD
Acetylcysteine—GSS—Metabolism—PIK3CA—kidney cancer	8.16e-06	6.88e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—PTEN—kidney cancer	8.11e-06	6.84e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—MAPK3—kidney cancer	7.96e-06	6.71e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.9e-06	6.66e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—GSTP1—kidney cancer	7.79e-06	6.57e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—MAPK1—kidney cancer	7.57e-06	6.39e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—APC—kidney cancer	7.56e-06	6.38e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—KIT—kidney cancer	7.56e-06	6.38e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—IGF2—kidney cancer	7.55e-06	6.37e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—CDH1—kidney cancer	7.54e-06	6.36e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—CDKN2B—kidney cancer	7.52e-06	6.34e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—KIT—kidney cancer	7.43e-06	6.27e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—ABCB1—kidney cancer	7.37e-06	6.22e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—IGF1R—kidney cancer	7.3e-06	6.16e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—MAPK3—kidney cancer	7.22e-06	6.09e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—GSTM1—kidney cancer	7.16e-06	6.04e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—KRAS—kidney cancer	7.15e-06	6.03e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—BRAF—kidney cancer	7.11e-06	6e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—KRAS—kidney cancer	6.87e-06	5.79e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—MAPK1—kidney cancer	6.87e-06	5.79e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—IGF2—kidney cancer	6.85e-06	5.78e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—CDH1—kidney cancer	6.84e-06	5.77e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—CDKN2B—kidney cancer	6.82e-06	5.75e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—CYP1A1—kidney cancer	6.78e-06	5.72e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—IGF1R—kidney cancer	6.62e-06	5.59e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Innate Immune System—PIK3CA—kidney cancer	6.57e-06	5.54e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—KRAS—kidney cancer	6.48e-06	5.47e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—RAF1—kidney cancer	6.43e-06	5.42e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—RELA—kidney cancer	6.4e-06	5.4e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—ERBB2—kidney cancer	6.36e-06	5.37e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Adaptive Immune System—PIK3CA—kidney cancer	6.31e-06	5.32e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—MTOR—kidney cancer	6.28e-06	5.29e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—CD4—kidney cancer	6.27e-06	5.28e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—KRAS—kidney cancer	6.23e-06	5.25e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—HIF1A—kidney cancer	6.01e-06	5.07e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—TSC2—kidney cancer	6e-06	5.06e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Innate Immune System—PIK3CA—kidney cancer	5.96e-06	5.02e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—RAF1—kidney cancer	5.94e-06	5.01e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—CDKN1B—kidney cancer	5.89e-06	4.97e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—ERBB2—kidney cancer	5.87e-06	4.95e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—RAF1—kidney cancer	5.83e-06	4.92e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—RELA—kidney cancer	5.8e-06	4.9e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—MTOR—kidney cancer	5.8e-06	4.89e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—CD4—kidney cancer	5.78e-06	4.88e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—ERBB2—kidney cancer	5.77e-06	4.86e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—IL2—kidney cancer	5.77e-06	4.86e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—KDR—kidney cancer	5.75e-06	4.85e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—PTGS2—kidney cancer	5.74e-06	4.84e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Adaptive Immune System—PIK3CA—kidney cancer	5.72e-06	4.83e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—MTOR—kidney cancer	5.69e-06	4.8e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—CD4—kidney cancer	5.68e-06	4.79e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—JUN—kidney cancer	5.61e-06	4.73e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.57e-06	4.7e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—CTNNB1—kidney cancer	5.57e-06	4.69e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—HIF1A—kidney cancer	5.45e-06	4.6e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—CDKN1B—kidney cancer	5.44e-06	4.59e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—TSC2—kidney cancer	5.44e-06	4.59e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—PTEN—kidney cancer	5.42e-06	4.58e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—CDKN1B—kidney cancer	5.34e-06	4.51e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—APC—kidney cancer	5.3e-06	4.47e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—KIT—kidney cancer	5.3e-06	4.47e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—IL2—kidney cancer	5.23e-06	4.41e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—KDR—kidney cancer	5.21e-06	4.4e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—CTNNB1—kidney cancer	5.14e-06	4.33e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—JUN—kidney cancer	5.09e-06	4.29e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—POMC—kidney cancer	5.06e-06	4.27e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—CTNNB1—kidney cancer	5.05e-06	4.26e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—POMC—kidney cancer	5.04e-06	4.25e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—PTEN—kidney cancer	5.01e-06	4.22e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—BRAF—kidney cancer	4.98e-06	4.2e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—PTEN—kidney cancer	4.92e-06	4.15e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—KIT—kidney cancer	4.8e-06	4.05e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—APC—kidney cancer	4.8e-06	4.05e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—MAPK3—kidney cancer	4.63e-06	3.91e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—POMC—kidney cancer	4.57e-06	3.86e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—BRAF—kidney cancer	4.51e-06	3.81e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—MAPK1—kidney cancer	4.41e-06	3.72e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—MAPK3—kidney cancer	4.28e-06	3.61e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—MAPK3—kidney cancer	4.2e-06	3.54e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—KRAS—kidney cancer	4.17e-06	3.51e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—MYC—kidney cancer	4.16e-06	3.51e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—RAF1—kidney cancer	4.16e-06	3.51e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—RELA—kidney cancer	4.14e-06	3.49e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—ERBB2—kidney cancer	4.11e-06	3.47e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—MAPK1—kidney cancer	4.07e-06	3.43e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—MTOR—kidney cancer	4.06e-06	3.42e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—PTGS2—kidney cancer	4.03e-06	3.4e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—MAPK1—kidney cancer	4e-06	3.37e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—KRAS—kidney cancer	3.85e-06	3.24e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Immune System—PIK3CA—kidney cancer	3.83e-06	3.23e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—CDKN1B—kidney cancer	3.81e-06	3.21e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—KRAS—kidney cancer	3.78e-06	3.19e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—RAF1—kidney cancer	3.77e-06	3.18e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—RELA—kidney cancer	3.75e-06	3.17e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—ERBB2—kidney cancer	3.73e-06	3.15e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—IL2—kidney cancer	3.73e-06	3.14e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—MTOR—kidney cancer	3.68e-06	3.1e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—CCND1—kidney cancer	3.63e-06	3.06e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—JUN—kidney cancer	3.63e-06	3.06e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—CTNNB1—kidney cancer	3.6e-06	3.03e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Disease—PIK3CA—kidney cancer	3.53e-06	2.98e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—PTEN—kidney cancer	3.52e-06	2.97e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—PTEN—kidney cancer	3.51e-06	2.96e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Immune System—PIK3CA—kidney cancer	3.47e-06	2.93e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—CDKN1B—kidney cancer	3.45e-06	2.91e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—IL2—kidney cancer	3.38e-06	2.85e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—CCND1—kidney cancer	3.29e-06	2.78e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—JUN—kidney cancer	3.29e-06	2.77e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—CTNNB1—kidney cancer	3.26e-06	2.75e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—PTEN—kidney cancer	3.18e-06	2.68e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—VEGFA—kidney cancer	3.17e-06	2.67e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—MAPK3—kidney cancer	3e-06	2.53e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—MYC—kidney cancer	2.91e-06	2.46e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—VEGFA—kidney cancer	2.87e-06	2.42e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—MAPK1—kidney cancer	2.85e-06	2.4e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—MAPK3—kidney cancer	2.72e-06	2.29e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—KRAS—kidney cancer	2.69e-06	2.27e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—MYC—kidney cancer	2.64e-06	2.23e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—MAPK1—kidney cancer	2.59e-06	2.18e-05	CbGpPWpGaD
Acetylcysteine—SLCO1B1—Metabolism—PIK3CA—kidney cancer	2.48e-06	2.09e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—PIK3CA—kidney cancer	2.47e-06	2.09e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—KRAS—kidney cancer	2.44e-06	2.06e-05	CbGpPWpGaD
Acetylcysteine—CHUK—Signaling Pathways—TP53—kidney cancer	2.39e-06	2.02e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—PIK3CA—kidney cancer	2.24e-06	1.89e-05	CbGpPWpGaD
Acetylcysteine—IKBKB—Signaling Pathways—TP53—kidney cancer	2.17e-06	1.83e-05	CbGpPWpGaD
